Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus

Summary Background Esophageal cancer is a very common malignant tumor in China, especially esophageal squamous cell carcinoma (ESCC), but there is currently no effective treatment for patients after first-line chemotherapy failure. Apatinib has shown promising outcomes in treatment with various solid tumors. Objectives To evaluate the clinical efficacy and safety of apatinib combined with S-1 in the treatment of advanced ESCC patients after first-line chemotherapy failure. Methods In this prospective study, fifteen patients with advanced ESCC who failed first-line chemotherapy were enrolled from Nov 2016 to Apr 2019. Patients received the combination therapy with apatinib (250-500 mg, once daily) plus S-1 (40–60 mg based on body surface area, twice daily). Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), disease control rate (DCR) and objective response rate (ORR). Adverse events (AEs) were recorded to evaluate the safety. Results A total of 12 patients were included in the efficacy analysis. The median PFS was 6.23 months, and the median OS was 8.83 months. Two (16.67%) patients achieved partial remission, 9 patients (75.00%) achieved stable disease and 1 (8.33%) patient achieved progressive disease. DCR and ORR was 91.67%and 16.67%, respectively. Most frequent AEs were hypertension, myelosuppression, weakness, hemorrhage, hand-foot syndrome, total bilirubin elevation, sick, proteinuria, oral ulcer, loss of appetite, and transaminase elevation. The most AEs were in grade I~II. Conclusion The combination therapy of apatinib plus S-1 was effective and well tolerated in the treatment of advanced ESCC patients after first-line chemotherapy failure. The combination therapy has the potential to be a potent therapeutic option for advanced ESCC patients after first-line chemotherapy failure.

Download Full-text

Clinical Efficacy and Safety of Combination Therapy with Amlodipine and Olmesartan or an Olmesartan/Hydrochlorothiazide Compound for Hypertension: A Prospective, Open-Label, and Multicenter Clinical Trial in China

Current Therapeutic Research ◽

10.1016/j.curtheres.2015.09.001 ◽

2019 ◽

Vol 90 ◽

pp. 99-105

Author(s):

Pingjin Gao ◽

Kezhi Mei ◽

Hongwei Li ◽

Qiuyan Dai ◽

Xingui Guo ◽

...

Keyword(s):

Clinical Trial ◽

Combination Therapy ◽

Clinical Efficacy ◽

Efficacy And Safety ◽

Multicenter Clinical Trial ◽

Open Label

Download Full-text

The clinical efficacy and safety of micafungin–itraconazole combination therapy in patients with pulmonary aspergilloma

Journal of Infection and Chemotherapy ◽

10.1007/s10156-012-0391-x ◽

2012 ◽

Vol 18 (5) ◽

pp. 668-674 ◽

Cited By ~ 12

Author(s):

Masaki Fujita ◽

Hiroshi Ouchi ◽

Eiji Harada ◽

Satoshi Ikegame ◽

Yoichi Nakanishi ◽

...

Keyword(s):

Combination Therapy ◽

Clinical Efficacy ◽

Efficacy And Safety ◽

Pulmonary Aspergilloma

Download Full-text

Xiyanping Plus Azithromycin Chemotherapy in Pediatric Patients with Mycoplasma pneumoniae Pneumonia: A Systematic Review and Meta-Analysis of Efficacy and Safety

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2019/2346583 ◽

2019 ◽

Vol 2019 ◽

pp. 1-9 ◽

Cited By ~ 1

Author(s):

Qiao Li ◽

Zhi-Yong Li ◽

Jie Zhang ◽

Wen-Na Guo ◽

Xiao-Meng Xu ◽

...

Keyword(s):

Systematic Review ◽

Combination Therapy ◽

Mycoplasma Pneumoniae ◽

Clinical Efficacy ◽

Pediatric Patients ◽

Meta Analysis ◽

Medicinal Preparation ◽

Efficacy And Safety ◽

Standard Mean Difference ◽

Disappearance Time

Background. Xiyanping injection (XYP) is a well-known Chinese medicinal preparation reputed as a most effective alternative to antibiotics. XYP has been widely used in combination therapies to treat various infectious diseases, among which XYP plus azithromycin (AZM) chemotherapy is often used for the treatment of Mycoplasma pneumoniae pneumonia in pediatric patients (p-MPP) in China. Objective. The present study just aimed to confirm whether XYP can improve the clinical efficacy and safety of AZM chemotherapy for p-MPP by performing meta-analysis and systematic review. Methods. A meta-analysis was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The randomized controlled trials (RCTs) concerning XYP plus AZM chemotherapy for p-MPP were selected, for which the main outcomes included overall response rate (ORR), antipyretic time, cough disappearance time, lung wet Rales disappearance time, hospitalization duration, and adverse drug reactions (ADRs). Based on the data extracted, the meta-analysis was conducted by using a standard data extraction form. Results. Nine RCTs involving 963 patients were included for meta-analysis. More concretely, the combination therapy showed the risk ratio (RR) and 95% confidence intervals (CI) of ORR and ADRs as (RR, 1.21 [95% CI, 1.15, 1.28]) and (RR, 0.37 [95% CI, 0.27, 0.51]), respectively. And other major outcomes were as follows: hospitalization durations (standard mean difference (SMD), −1.32 [95% CI, −1.48, −1.16]), antipyretic time (SMD, −1.26 [95% CI, −1.70, −0.83]), cough disappearance time (SMD, −1.07 [95% CI, −1.38, −0.75]), and the disappearance time of lung wet Rales (SMD, −0.83 [95% CI, −1.07, −0.60]). With statistically significant differences in various aspects, the combination therapy plus XYP displayed obvious advantages in contrast to AZM alone. Conclusion. Overall, XYP might reduce the incidence of ADRs and significantly improve the clinical efficacy for p-MPP receiving AZM chemotherapy.

Download Full-text